When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion…
Georgina V. Long, BSc, PhD, MBBS, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital…
Scott Tykodi, MD, PhD, physician at Seattle Cancer Care Alliance, associate professor in the Division of Medical Oncology at University of Washington Medicine, and associate professor in the…
Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses the promise of immuno-oncology in the treatment of patients with mesothelioma. In second line, nivolumab and pembrolizumab are…
Hui-Zi Chen, MD, PhD, assistant professor in the Department of Internal Medicine, Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center – James, discusses the…
Ragini R. Kudchadkar, MD, associate professor Department of Hematology and Medical Oncology, associate director of Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory University School of…
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy…
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…
Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
